Ayumi Hongo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayumi Hongo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Amy Codd
Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, Wales, United Kingdom
1 shared publication- Junichi Kodama
Department of Obstetrics and Gynecology, Hiroshima City Hospital, Hiroshima 730‑8518, Japan
1 shared publication K. Nakamura
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; and †Department of Obstetrics and Gynecology, Inner Mongolia Agriculture University Hospital, Huhehaote, China
1 shared publicationMunehide Nakatsugawa
Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
1 shared publicationN. Seki
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; and †Department of Obstetrics and Gynecology, Inner Mongolia Agriculture University Hospital, Huhehaote, China
1 shared publicationNoriko Kawai
Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
1 shared publication
Latest Publications
- 15 May 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 202 (10) , 2849-2855
Upstream Position of Proline Defines Peptide–HLA Class I Repertoire Formation and CD8+ T Cell Responses
Cytotoxic CD8+ T lymphocytes (CTLs) recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathological conditions such as cancer. Difficulty in predicting HLA class I ligands is attributed to the complexity of the Ag processing pathway across the cytosol and the endoplasmic reticulum. By means of HLA ligandome analysis using mass spectrometry, we collected natural HLA class I ligands on a large scale and analyzed the source-protein sequences flanking the ligands. This comprehensive analysis revealed that the frequency of proline at amino acid positions 1–3 upstream of the ligands was selectively decreased. The depleted proline signature was the strongest among all the upstream and downstream profiles. Experiments using live cells demonstrated that the presence of proline at upstream positions 1–3 attenuated CTL responses against a model epitope. Other experiments, in which N-terminal–flanking Ag precursors were confined in the endoplasmic reticulum, demonstrated an inability to remove upstream prolines regardless of their positions, suggesting a need for synergistic action across cellular compartments for making the proline signature. Our results highlight, to our knowledge, a unique role and position of proline for inhibiting downstream epitope presentation, which provides a rule for defining natural peptide–HLA class I repertoire formation and CTL responses. Key Points Proteomics analysis shows the upstream proline signature of HLA class I ligands. Proline at upstream positions 1–3 attenuates CTL responses to a downstream epitope. The finding contributes to prediction of naturally presented CTL epitopes.
- 15 May 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 202 (10) , 2849-2855
Upstream Position of Proline Defines Peptide–HLA Class I Repertoire Formation and CD8+ T Cell Responses
Cytotoxic CD8+ T lymphocytes (CTLs) recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathological conditions such as cancer. Difficulty in predicting HLA class I ligands is attributed to the complexity of the Ag processing pathway across the cytosol and the endoplasmic reticulum. By means of HLA ligandome analysis using mass spectrometry, we collected natural HLA class I ligands on a large scale and analyzed the source-protein sequences flanking the ligands. This comprehensive analysis revealed that the frequency of proline at amino acid positions 1–3 upstream of the ligands was selectively decreased. The depleted proline signature was the strongest among all the upstream and downstream profiles. Experiments using live cells demonstrated that the presence of proline at upstream positions 1–3 attenuated CTL responses against a model epitope. Other experiments, in which N-terminal–flanking Ag precursors were confined in the endoplasmic reticulum, demonstrated an inability to remove upstream prolines regardless of their positions, suggesting a need for synergistic action across cellular compartments for making the proline signature. Our results highlight, to our knowledge, a unique role and position of proline for inhibiting downstream epitope presentation, which provides a rule for defining natural peptide–HLA class I repertoire formation and CTL responses. Key Points Proteomics analysis shows the upstream proline signature of HLA class I ligands. Proline at upstream positions 1–3 attenuates CTL responses to a downstream epitope. The finding contributes to prediction of naturally presented CTL epitopes.
- 1 May 2006
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 16 (3) , 1401-1406
Heparanase expression in both normal endometrium and endometrial cancer
- 1 May 2006
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 16 (3) , 1401-1406
Heparanase expression in both normal endometrium and endometrial cancer